Testing effectiveness (Phase 2)Active Not RecruitingNCT05553834
What this trial is testing
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Duke University 60